Omicron variant neutralizing antibodies following BNT162b2 BA.4/5 versus mRNA1273 BA.1 bivalent vaccination in patients with end-stage kidney disease

Thumbnail image

Download files

DOI

https://doi.org/10.1038/s41467-023-41678-9

Language of the publication
English
Date
2023-09-27
Type
Article
Author(s)
  • Yau, Kevin
  • Kurtesi, Alexandra
  • Qi, Freda
  • Delgado-Brand, Melanie
  • Tursun, Tulunay R.
  • Hu, Queenie
  • Dhruve, Miten
  • Kandel, Christopher
  • Enilama, Omosomi
  • Levin, Adeera
  • Jiang, Yidi
  • Hardy, W. Rod
  • Yuen, Darren A.
  • Perl, Jeffrey
  • Chan, Christopher T.
  • Leis, Jerome A.
  • Oliver, Matthew J.
  • Colwill, Karen
  • Gingras, Anne-Claude
  • Hladunewich, Michelle A.
Publisher
Nature Portfolio

Abstract

Neutralization of Omicron subvariants by different bivalent vaccines has not been well evaluated. This study characterizes neutralization against Omicron subvariants in 98 individuals on dialysis or with a kidney transplant receiving the BNT162b2 (BA.4/BA.5) or mRNA-1273 (BA.1) bivalent COVID-19 vaccine. Neutralization against Omicron BA.1, BA.5, BQ.1.1, and XBB.1.5 increased by 8-fold one month following bivalent vaccination. In comparison to wild-type (D614G), neutralizing antibodies against Omicron-specific variants were 7.3-fold lower against BA.1, 8.3-fold lower against BA.5, 45.8-fold lower against BQ.1.1, and 48.2-fold lower against XBB.1.5. Viral neutralization was not significantly different by bivalent vaccine type for wild-type (D614G) (P = 0.48), BA.1 (P = 0.21), BA.5 (P = 0.07), BQ.1.1 (P = 0.10), nor XBB.1.5 (P = 0.10). Hybrid immunity conferred higher neutralizing antibodies against all Omicron subvariants. This study provides evidence that BNT162b2 (BA.4/BA.5) and mRNA-1273 (BA.1) induce similar neutralization against Omicron subvariants, even when antigenically divergent from the circulating variant.

Subject

  • Health

Rights

Peer review

Yes

Open access level

Gold

Identifiers

ISSN
2041-1723

Article

Journal title
Nature Communications
Journal volume
14
Journal issue
1
Article number
6041
Accepted date
2023-09-14
Submitted date
2023-04-27

Citation(s)

Yau, K., Kurtesi, A., Qi, F. et al. Omicron variant neutralizing antibodies following BNT162b2 BA.4/5 versus mRNA-1273 BA.1 bivalent vaccination in patients with end-stage kidney disease. Nat Commun 14, 6041 (2023). https://doi.org/10.1038/s41467-023-41678-9

Download(s)

URI

Collection(s)

Communicable diseases

Full item page

Full item page

Page details

Date modified: